ストックスクリーナーアプリを入手
98.90
0.28%
0.28
アフターアワーズ：
97.52
-1.38
-1.40%
Mirum Pharmaceuticals Inc (MIRM) 最新ニュース
Gilead wins hepatitis D drug approval as two Bay Area rivals line up their drugs - The Business Journals
US604749AC5 Bond Analysis — Key Metrics - TradingView
US604749AC5 Bond Price and Chart — FWB:US604749AC5 - TradingView
Mirum’s US$600 Million Zero-Coupon Convertible Note Issue Might Change The Case For Investing In Mirum Pharmaceuticals (MIRM) - Yahoo Finance
Behavioral Patterns of MIRM and Institutional Flows - Stock Traders Daily
Mirum Pharmaceuticals, Inc.common stock (NQ: MIRM - The Chronicle-Journal
MIRM Stock Price, Quote & Chart | MIRUM PHARMACEUTICALS INC (NASDAQ:MIRM) - ChartMill
Mirum Pharmaceuticals Set to Present Key Data at International L - GuruFocus
Mirum Pharma: A rare disease growth story to watch - MSN
Mirum Pharmaceuticals to Present Data Showcasing Leadership in Rare Liver Diseases at the EASL International Liver Congress 2026 - Business Wire
Mirum Pharmaceuticals Issues $690 Million Convertible Senior Notes - TipRanks
MIRM: Clinical and commercial catalysts drive growth, with major pipeline and BD milestones ahead - TradingView
Mirum Pharma: A Rare Disease Growth Story to Watch - sharewise.com
Wolfe Research initiates coverage of Mirum Pharmaceuticals (MIRM) with outperform recommendation - MSN
Mirum Pharmaceuticals director Saira Ramasastry sells $218,940 stock By Investing.com - Investing.com Nigeria
This Interface Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Wolfe Research initiates Mirum stock with outperform rating By Investing.com - Investing.com Canada
Mirum Pharmaceuticals director Saira Ramasastry sells $218,940 stock - Investing.com UK
[Form 4] Mirum Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Mirum Pharmaceuticals (NASDAQ: MIRM) sells $600M 2032 converts, to refinance 2029 notes - Stock Titan
Mirum Pharmaceuticals (MIRM) price target increased by 16.75% to 149.29 - MSN
Mirum Pharmaceuticals prices $600M senior notes - MSN
2,000-share sale via option exercise — MIRM (NASDAQ: MIRM) Form 144 - Stock Titan
Mirum's Q1 earnings & revenues beat estimates, 2026 view raised - MSN
Mirum Pharmaceuticals (MIRM) moves 5.1% higher: Will this strength last? - MSN
Latham & Watkins Advises on Mirum Pharmaceuticals’ US$600 Million Convertible Senior Notes Offering - Latham & Watkins LLP
Mirum Pharmaceuticals reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
(MIRM) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Mirum Pharmaceuticals stock hits all-time high at 112.47 USD By Investing.com - Investing.com South Africa
Mirum Pharmaceuticals stock (US60471A1034): Hits all-time high amid $600M debt deal - AD HOC NEWS
Mirum Pharmaceuticals stock hits all-time high at 112.47 USD - Investing.com
Mirum Pharmaceuticals Prices $600 Million Private Debt Offering - Moomoo
Mirum Pharmaceuticals Prices $600.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2029 Convertible Notes - BioSpace
Mirum plans $600 million convertible notes offering due 2032 By Investing.com - Investing.com South Africa
Mirum prices $600m convertible notes offering due 2032 By Investing.com - Investing.com South Africa
Mirum prices $600m convertible notes offering due 2032 - Investing.com
Mirum Pharmaceuticals Prices $600.0 Million Convertible Senior Notes Offering - TradingView
Mirum raises $600M in 0% convertible notes, starts 2029 debt swap - Stock Titan
Mirum pharmaceuticals announces proposed convertible senior notes offering - marketscreener.com
Mirum Pharmaceuticals Announces Proposed Convertible Senior Notes Offering - TradingView
0.98%
0.12%
大文字化:
|
ボリューム (24 時間):